News25/Ratings12
News · 26 weeks73+8%
2025-12-282026-06-21
Mix3290d
- Insider15(47%)
- Other9(28%)
- SEC Filings7(22%)
- Analyst1(3%)
Latest news
25 items- INSIDERChief Operating Officer Chappell Todd sold $34,309 worth of shares (3,168 units at $10.83), decreasing direct ownership by 16% to 16,964 units (SEC Form 4) to satisfy withholding tax4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERChief Scientific Officer Vincent Loic A sold $37,017 worth of shares (3,418 units at $10.83), decreasing direct ownership by 16% to 18,297 units (SEC Form 4) (withholding obligation)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERGeneral Counsel Cerio Jeffrey sold $71,575 worth of shares (6,609 units at $10.83), decreasing direct ownership by 16% to 35,293 units (SEC Form 4) (tax liability)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSenior Vice President, Finance Dolan Oliver sold $36,638 worth of shares (3,383 units at $10.83), decreasing direct ownership by 16% to 18,099 units (SEC Form 4) to satisfy withholding obligation4 - Korro Bio, Inc. (0001703647) (Issuer)
- SECSEC Form 144 filed by Korro Bio Inc.144 - Korro Bio, Inc. (0001703647) (Subject)
- INSIDERSEC Form 4 filed by Director Behbahani Ali4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 4 filed by Director Meyers Rachel4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 4 filed by Director Bermingham Nessan4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 4 filed by Director Knobil Katharine4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 4 filed by Director Formela Jean Francois4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERSEC Form 4 filed by Director Pearson Timothy R4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERPresident and CEO Aiyar Ram sold $196,673 worth of shares (15,152 units at $12.98), decreasing direct ownership by 17% to 74,848 units (SEC Form 4) to satisfy withholding tax4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERDirector Formela Jean Francois sold $39,897 worth of shares (2,860 units at $13.95) as part of a pre-agreed trading plan (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- INSIDERPresident and CEO Aiyar Ram was granted 50,000 shares, increasing direct ownership by 125% to 90,000 units (SEC Form 4)4 - Korro Bio, Inc. (0001703647) (Issuer)
- PRKorro to Present at the 2026 Jefferies Global Healthcare ConferenceCAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference being held in New York, NY on June 2nd- 4th, 2026. Dr. Aiyar's presentation will take place on Thursday, June 4, 2026, at 4:20 pm ET. About Korro Korro is a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a ne
- SECKorro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)Potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungsDemonstrated >90% editing of SERPINA1 transcript in vivo translating into ~90% repaired functional alpha-1 antitrypsin (AAT) protein in plasma in a mouse model of AATDDemonstrated a near elimination of active Z-protein production while showing progressive clearance of pre-existing aggregates in a mouse model of AATDPre-clinical data highlighted the possibility of repeat dose therapy to achieve the functional equivalent of a DNA modification without altering the genome CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Korro
- ANALYSTCitigroup initiated coverage on Korro Bio with a new price targetCitigroup initiated coverage of Korro Bio with a rating of Buy and set a new price target of $21.00
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.SCHEDULE 13G/A - Korro Bio, Inc. (0001703647) (Subject)
- PRKorro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee. Korro granted the new employee a nonstatutory stock option to purchase 3,000 shares of Korro's common stock at an exercise price of $11.20 per share, the closing price per share of Korro's common stock as reported by Nasdaq on the grant effective date, May 13, 2026. The option has a ten-year term and vests over four years, with 2
- SECSEC Form 424B3 filed by Korro Bio Inc.424B3 - Korro Bio, Inc. (0001703647) (Filer)
- SECSEC Form 10-Q filed by Korro Bio Inc.10-Q - Korro Bio, Inc. (0001703647) (Filer)
- SECKorro Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Korro Bio, Inc. (0001703647) (Filer)
- PRKorro Reports First Quarter 2026 Financial Results and Provides Corporate UpdateHosted virtual Analyst Day showcasing lead program KRRO-121's potential to be a first-in-class transformational treatment for hyperammonemia in patients with urea cycle disorders (UCDs) and hepatic encephalopathy (HE); regulatory filing for KRRO-121 expected in the second half of 2026Advanced early-stage research and development programs highlighted by a GalNac-conjugated oligonucleotide for alpha-1 antitrypsin deficiency (AATD); on track to announce development candidate in second quarter of 2026Executed oversubscribed $85 million private placement to support the achievement of value inflection points for multiple RNA editing clinical programs and extend cash runway into the second half of
- PRKorro to Participate in Upcoming Investor ConferencesCAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Chief Executive Officer and President, Jeffrey Cerio, SVP and General Counsel, Todd Chappell, Chief Operating Officer, and Loïc Vincent, Chief Scientific Officer, will participate in the following investor conferences: HCW 4th Annual BioConnect Nasdaq Investor ConferenceFormat: Fireside chat moderated by Mitchell Kapoor, Director and Senior Analyst, Biotechnology Equity Research, H.
KRRO FAQ
6 questionsWhere does KRRO stock trade?
Korro Bio Inc. (KRRO) is listed on NASDAQ.What sector and industry is KRRO in?
Korro Bio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Korro Bio Inc. go public?
Korro Bio Inc. (KRRO) completed its IPO in 2019.What are analysts saying about KRRO?
Korro Bio Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy with a $2100.00 price target on 2026-05-18. Recent price targets range from $1500.00 to $3000.00.What companies are similar to KRRO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KRRO side-by-side with any of them on Quantisnow.How can I track KRRO on Quantisnow?
Quantisnow aggregates Korro Bio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRRO to receive live email and push alerts on every new disclosure.